# Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

> **NCT05954871** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Colorectal Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** GDC-1971
- **DRUG:** Osimertinib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05954871
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-08
- **Primary completion:** 2025-09-16
- **Final completion:** 2025-09-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05954871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05954871, "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05954871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*